There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use

Detalles Bibliográficos
Autor principal: Trkulja, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691281/
https://www.ncbi.nlm.nih.gov/pubmed/36436621
http://dx.doi.org/10.1016/j.jinf.2022.11.016
_version_ 1784837005559988224
author Trkulja, Vladimir
author_facet Trkulja, Vladimir
author_sort Trkulja, Vladimir
collection PubMed
description
format Online
Article
Text
id pubmed-9691281
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-96912812022-11-25 There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use Trkulja, Vladimir J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-11-25 /pmc/articles/PMC9691281/ /pubmed/36436621 http://dx.doi.org/10.1016/j.jinf.2022.11.016 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Trkulja, Vladimir
There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
title There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
title_full There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
title_fullStr There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
title_full_unstemmed There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
title_short There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
title_sort there is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in covid-19 outpatients: a comment on two recent meta-analyses advocating its use
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691281/
https://www.ncbi.nlm.nih.gov/pubmed/36436621
http://dx.doi.org/10.1016/j.jinf.2022.11.016
work_keys_str_mv AT trkuljavladimir thereisnoreasonableevidencetosupportefficacyoffluvoxamineinpreventionofdiseasedeteriorationincovid19outpatientsacommentontworecentmetaanalysesadvocatingitsuse

Ejemplares similares